Refractory Angioimmunoblastic T-Cell Lymphoma

7 clinical trials · Condition

Record	Firm	Date
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998)	City of Hope Medical Center	2019-02-04
Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (NCT03593018)	The Lymphoma Academic Research Organisation	2018-11-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (NCT03278782)	M.D. Anderson Cancer Center	2017-11-14
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553)	Mayo Clinic	2017-05-17
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820)	Mayo Clinic	2017-04-04
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732)	M.D. Anderson Cancer Center	2012-10-29

Every clearance here is in the API, with alerts when new ones post.